Our Clinical Trials
PREFER NGS Registry
Solid TumorsPRospective rEgistry OF Advanced Stage cancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine (PREFER)
Lines of Therapy: 1st Line Metastatic and Locally Advanced